Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
Coya Therapeutics announced that it will present the design of its ongoing ALSTARS trial at the ENCALS 2026 meeting in Madrid. The Phase 2, randomized, double-blind, placebo-controlled study evaluates COYA 302, a proprietary biologic combination therapy, for the treatment of ALS.
Key figures
- Drug Name
- COYA 302
- Phase Of Trial
- Phase 2
- Clinical trial id
- NCT07161999
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.